WO2008122098A1 - Composition for promoting the maintenance and function of muscle-specific progenitor cells - Google Patents
Composition for promoting the maintenance and function of muscle-specific progenitor cells Download PDFInfo
- Publication number
- WO2008122098A1 WO2008122098A1 PCT/CA2007/000545 CA2007000545W WO2008122098A1 WO 2008122098 A1 WO2008122098 A1 WO 2008122098A1 CA 2007000545 W CA2007000545 W CA 2007000545W WO 2008122098 A1 WO2008122098 A1 WO 2008122098A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- muscle
- composition
- creatine
- source
- mammal
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 210000003205 muscle Anatomy 0.000 title claims abstract description 35
- 238000012423 maintenance Methods 0.000 title abstract description 10
- 210000000130 stem cell Anatomy 0.000 title description 26
- 230000001737 promoting effect Effects 0.000 title description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 80
- 229960003624 creatine Drugs 0.000 claims abstract description 36
- 239000006046 creatine Substances 0.000 claims abstract description 36
- 210000001057 smooth muscle myoblast Anatomy 0.000 claims abstract description 34
- 210000004027 cell Anatomy 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 29
- 206010028311 Muscle hypertrophy Diseases 0.000 claims abstract description 19
- 230000012042 muscle hypertrophy Effects 0.000 claims abstract description 19
- 239000002243 precursor Substances 0.000 claims abstract description 16
- 241000124008 Mammalia Species 0.000 claims abstract description 15
- 230000001114 myogenic effect Effects 0.000 claims abstract description 14
- 230000004927 fusion Effects 0.000 claims abstract description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 30
- 229920000855 Fucoidan Polymers 0.000 claims description 27
- 150000003408 sphingolipids Chemical class 0.000 claims description 19
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 15
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 15
- 235000021283 resveratrol Nutrition 0.000 claims description 15
- 229940016667 resveratrol Drugs 0.000 claims description 15
- 230000004044 response Effects 0.000 claims description 5
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 230000000153 supplemental effect Effects 0.000 abstract description 24
- 230000024977 response to activity Effects 0.000 abstract description 13
- 210000002027 skeletal muscle Anatomy 0.000 abstract description 12
- 230000008439 repair process Effects 0.000 abstract description 7
- 230000008827 biological function Effects 0.000 abstract description 6
- 230000012010 growth Effects 0.000 abstract description 5
- 210000000419 skeletal muscle satellite cell Anatomy 0.000 abstract description 3
- 230000008238 biochemical pathway Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 description 20
- 235000015872 dietary supplement Nutrition 0.000 description 19
- 230000001939 inductive effect Effects 0.000 description 12
- 150000002148 esters Chemical class 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 239000007894 caplet Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- 210000001087 myotubule Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000009469 supplementation Effects 0.000 description 8
- 240000001341 Reynoutria japonica Species 0.000 description 6
- 235000018167 Reynoutria japonica Nutrition 0.000 description 6
- 241000015177 Saccharina japonica Species 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 description 5
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 5
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 5
- 230000007910 cell fusion Effects 0.000 description 5
- 229960004826 creatine monohydrate Drugs 0.000 description 5
- 102000003800 Selectins Human genes 0.000 description 4
- 108090000184 Selectins Proteins 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- PBFDKFLAOSYLOL-DFWYDOINSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;(2s)-5-oxopyrrolidine-2-carboxylic acid Chemical compound NC(=N)N(C)CC([OH2+])=O.[O-]C(=O)[C@@H]1CCC(=O)N1 PBFDKFLAOSYLOL-DFWYDOINSA-N 0.000 description 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- 241001261506 Undaria pinnatifida Species 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- -1 e.g. Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000021268 myoblast fusion Effects 0.000 description 2
- 230000004070 myogenic differentiation Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000025175 skeletal muscle hypertrophy Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- MBBREGJRSROLGD-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MBBREGJRSROLGD-UHFFFAOYSA-N 0.000 description 1
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical class OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 108010061299 CXCR4 Receptors Proteins 0.000 description 1
- 102000012000 CXCR4 Receptors Human genes 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 241000227647 Fucus vesiculosus Species 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000008934 Muscle Proteins Human genes 0.000 description 1
- 108010074084 Muscle Proteins Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 102000008212 P-Selectin Human genes 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000008690 Pausinystalia yohimbe Nutrition 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical class CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000026214 Skeletal muscle atrophy Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000007646 directional migration Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020650 eye health related herbal supplements Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Chemical class 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000013663 muscle adaptation Effects 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 210000003130 muscle precursor cell Anatomy 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000021135 plant-based food Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000020095 red wine Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011667 skeletal muscle adaptation Effects 0.000 description 1
- 230000025185 skeletal muscle atrophy Effects 0.000 description 1
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 1
- 238000001374 small-angle light scattering Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004137 sphingolipid metabolism Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical class [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 230000007419 viral reactivation Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention is directed towards a composition and method for inducing muscle hypertrophy via satellite cells fusion to muscle fibres and for inducing a substantially simultaneous replenishment of myogenic precursor cells in response to exercise.
- Body composition including muscle, is influenced both by genetic factors and environmental stimuli.
- Important environmental factors or stimuli which effect muscle metabolism include food intake and exercise (Rennie MJ. Body maintenance and repair: how food and exercise keep the musculoskeletal system in good shape. Exp Physiol. 2005 Jul;90(4):427-36).
- Gene and protein expression patterns change in response to stimuli. This results in muscle adaptations such as muscle atrophy (loss) or muscle hypertrophy (gain).
- the determination of muscle loss or gain is the net effect of both positive and negative factors governing muscle development.
- 'True' muscle hypertrophy can be defined as "as an increase in fiber diameter without an apparent increase in the number of muscle fibers, accompanied by enhanced protein synthesis and augmented contractile force" (Sartorelli V, Fulco
- Satellite cells are a small population of quiescent muscle precursor cells that occupy a "satellite" position immediately outside of muscle fibers (Mauro i A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961 Feb;9:493- 5). They are normally maintained in a quiescent state and become activated to fulfill roles of routine maintenance, repair and hypertrophy. Satellite cells are thought to be muscle-specific stem cells which are capable of producing large numbers of differentiated progeny as well as being capable of self-renewal (Collins CA, Partridge TA. Self-renewal of the adult skeletal muscle satellite cell. Cell Cycle. 2005 Oct;4(10): 1338-41).
- Satellite cells In order that satellite cells can fulfill their biological role, they • must become activated, proliferate, differentiate and fuse to existing muscle cells (Anderson JE. The satellite cell as a companion in skeletal muscle plasticity: currency, conveyance, clue, connector and colander. J Exp Biol. 2006 Jun;209(Pt 12):2276-92). In this way, multinucleate muscle fibers are maintained or increased in size in response to stimuli.
- Activation of satellite cells is essential for their proper function and is defined as "an entry into Gl from quiescence and mobilization" (Anderson JE, Wozniak AC. Satellite cell activation on fibers: modeling events in vivo—an invited review. Can J Physiol Pharmacol. 2004 May;82(5):300-10).
- One of the main factors which has been associated with the activation of satellite cells is nitric oxide (NO) (Anderson JE, Wozniak AC. Satellite cell activation on fibers: modeling events in vivo ⁇ an invited review. Can J Physiol Pharmacol. 2004 May;82(5):300-10).
- NO is a small, freely diffusible signaling molecule produced in muscle by neuronal NO- synthase.
- NO release is regulated by stretching in skeletal muscle and is thought to be responsible for early satellite cell activation in response to muscle injury in proximal and distal muscle fibers (Anderson JE. A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. MoI Biol Cell. 2000 May;l l(5):1859-74).
- NO activity is largely controlled by regulating the enzymes responsible for synthesizing NO - Nitric Oxide Synthases (NOSs). All major nitric oxide synthase (NOS) isoforms and splice variants, including a muscle-specific splice variant, are expressed in the skeletal muscles of all mammals (Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol Rev. 2001 Jan;81(l):209-237). Furthermore, the inner lining, or endothelium, of blood vessels uses NO to signal the surrounding smooth muscle to relax. This has the effect of dilating the artery thereby increasing blood flow in the affected region.
- NO has also been shown to play an important role in myoblast and satellite cell fusion (Pisconti A, Brunelli S, Di Padova M, De Palma C, Deponti D, Baesso S, Sartorelli V, Cossu G, Clementi E. Follistatin induction by nitric oxide through cyclic GMP: a tightly regulated signaling pathway that controls myoblast fusion. J Cell Biol. 2006 Jan 16;172(2):233-44) thereby contributing to muscle maintenance and growth.
- Myoblast fusion is itself a complex process involving migration, recognition and adhesion, each involving several mechanisms and factors.
- stem cells are to function properly, their pools must be maintained. Therefore, a defining feature of stem cells is their ability of self-renewal in addition to being able to produce differentiated cells (Collins CA, Partridge TA. Self-renewal of the adult skeletal muscle satellite cell. Cell Cycle. 2005 Oct;4(10):1338-41). Research has shown that the pool of satellite cells is maintained not only by self- renewal but also by contributions from the hematopoietic, i.e. blood, system (Doyonnas R, LaBarge MA, Sacco A, Charlton C, Blau HM. Hematopoietic contribution to skeletal muscle regeneration by myelomonocytic precursors. Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13507-12).
- hematopoietic stem cells contribute to muscle maintenance, the cells must migrate to the area at which they are required for repair or maintenance. This directed migration of stem/progenitor cells is termed 'mobilization'.
- a main mechanism for the mobilization of stem cells is through the release of signaling molecules at the site of the stem cell requirement wherein the stem cells express the corresponding cell surface receptors (Papayannopoulou T. Current mechanistic scenarios in hematopoietic stem/progenitor cell mobilization. Blood. 2004 Mar l;103(5):1580-5).
- CXCR-4 receptor An important receptor-ligand system for the relationship between the hematopoietic and muscle systems is the CXCR-4 receptor and the secreted chemokine, SDF-I (Ratajczak MZ, Majka M, Kucia M, Drukala J, Pietrzkowski Z, Peiper S, Janowska-Wieczorek
- SDF-I Rosatajczak MZ, Majka M, Kucia M, Drukala J, Pietrzkowski Z, Peiper S, Janowska-Wieczorek
- the present invention comprises, in accordance with an embodiment thereof, the administration, to a mammal, of a composition comprising at least creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters of creatine and a source of fucoidan, to induce muscle hypertrophy via satellite cell fusion to muscle fibres and to provide substantially coincident support for the replenishment of myogenic precursor cells in response to exercise.
- a composition comprising at least creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters of creatine and a source of fucoidan, to induce muscle hypertrophy via satellite cell fusion to muscle fibres and to provide substantially coincident support for the replenishment of myogenic precursor cells in response to exercise.
- the present invention is directed towards inducing muscle hypertrophy via satellite cell fusion to muscle fibres and provide substantially coincident support for the replenishment of myogenic precursor cells in response to exercise.
- the composition and method of the present invention accomplishes said support by encouraging multiple distinct aspects of muscle-specific progenitor cell biology.
- the term "muscle-specific progenitor cell” refers to any undifferentiated cell that is, or will be, at any time, capable of differentiating into any cell type which contributes to mature, functional adult skeletal muscle. This, for the purposes of the present disclosure, includes satellite cells and any other multi-potent cells such as hematopoietic stem cells which have the potential to contribute to skeletal muscle hypertrophy and growth, development or maintenance. It is herein understood that, despite a lack of consensus regarding nomenclature, there exists a continuum of cell types that lie between a classical pluripotent 'embryonic stem cell' capable of giving rise to all cell types on one extreme and a terminally-differentiated cell on the other extreme.
- undifferentiated cell types having increasingly limited developmental potential progressing from an embryonic stem cell toward a terminally-differentiated cell exist between said extremes. Furthermore, it is herein understood that such undifferentiated cells with limited, yet still multiple, developmental possibilities are generally termed 'tissue- specific stem cells'. However, undifferentiated cells with only one developmental possibility are generally termed 'progenitor cells'.
- Ingredients of the present composition may also be fine-milled in order to improve the immediacy of absorption, and thus the rate of bioavailability upon consumption by an individual.
- the fine-milling techniques and the immediacy of absorption employed in the present invention are disclosed in U.S. Patent Application No. 11/709,526, entitled “Method For Increasing The Rate And Consistency Of Bioavailability Of Supplemental Dietary Ingredients” and U.S. Patent Application No. 11/709,525, entitled “Method for a Supplemental Dietary Composition Having a Multi-Phase Dissolution Profile,” both herein incorporated fully by reference.
- rate of bioavailability is increased via a narrowing of particle size range and a concomitant reduction in the average particle size, improving the immediacy of absorption of said supplemental dietary ingredient. Furthermore, the consistency of dissolution, and thus the absorption of orally administered supplemental dietary ingredients, is improved by the fine-milled process.
- fine-milled and/or fine-milling refers to the process of micronization.
- Micronization is a mechanical process that involves the application of force to a particle, thereby resulting in a reduction in the size of the particle.
- the force in the case of micronization may be applied in any manner such as, e.g., the collision of particles at high rates of speed, grinding, or by an air-jet micronizer.
- fine-milled particles are obtained by jet- milling with nitrogen and compressed air.
- particle size refers to the diameter of the particle.
- average particle size means that at least 50% of the particles in a sample will have the specified particle size.
- at least 80% of the particles in a sample will have the specified particle size, and more preferably, at least 90% of the particles in a given sample will have the specified particle size.
- the preferred particle size range for fine-milled particles is between 2 and 50 microns.
- Methods for particle size determination which may be employed are, for example, sieves, sedimentation, electrozone sensing (Coulter counter), microscopy, and/or Low Angle Laser Light Scattering.
- the preferred methods for the particle size determination of the present invention are the methods which are most commonly used in the pharmaceutical industry, such as laser diffraction, e.g., via light scattering Coulter Delsa 440SX.
- the fine-milling process may be employed in the processing of one or more of the ingredients of the present invention in the dosage forms of tablets, e.g., immediate-release film coated, modified-release and fast-dissolving; capsules, e.g., immediate-release and modified-release; liquid dispersions; powders; drink mixes, etc. Creatine
- Creatine use has been thoroughly studied and is well-established as a beneficial dietary supplement for replenishing energy stores in working muscle cells (Greenhaff PL, Bodin K, Soderlund K, Hultman E. Effect of oral creatine supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol. 1994 May;266(5 Pt l):E725-30).
- the resultant increase in muscular energy stores from creatine supplementation in an individual, combined with physical exercise leads to increased strength, and a reduction in fatigue resulting from high-intensity exercise (Greenhaff PL, Casey A, Short AH, Harris R, Soderlund K, Hultman E.
- the supplemental composition comprises creatine or derivatives thereof.
- a serving of the supplemental composition comprises from about 1.00 g to about 10.00 g of creatine or derivatives thereof.
- the preferred dosage of a serving of the supplemental composition of the present invention comprises about 3.50 g of creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters of creatine.
- the creatine may be present in various embodiments of the present invention as creatine salts of malate, maleate, fumarate, tartrate, citrate, succinate, pyruvate, pyroglutamate, glutamate or any other pharmaceutically acceptable salt as known in the art.
- the creatine may be present in various embodiments of the present invention as creatine esters of phosphate, sulphate or any other pharmaceutically acceptable esters as known in the art.
- the present invention may further comprise creatine pyroglutamate as a pharmaceutically acceptable derivative of creatine.
- a serving of the supplemental composition may comprise from about 0.005 g to about 0.10 g of creatine pryoglutamate.
- the preferred dosage of a serving of the supplemental composition comprises about 0.01 g of creatine pyroglutamate.
- the present invention may further comprise at least a portion of the creatine or pharmaceutically acceptable salts or esters thereof in a fine-milled format.
- the supplemental composition comprises fine-milled creatine or pharmaceutically acceptable salts or esters of said creatine.
- a serving of the supplemental composition comprises from about 0.005 g to about 0.05 g of fine-milled creatine or pharmaceutically acceptable salts or esters of said creatine.
- the preferred dosage of a serving of the supplemental composition comprises about 0.02 g of fine-milled creatine or pharmaceutically acceptable salts or esters of said creatine.
- Fucoidans are naturally-occurring sulfated sugar polymers. They are constituents of edible seaweed and have been consumed by humans for centuries. The specific type of fucoidan differs dependent upon the source. Brown seaweed, in particular, is a source of branched-chain Fucoidans and several species have been used experimentally as a source of Fucoidans including Fucus vesiculosus, Undaria pinnatifida and Laminaria japonica. One of the main and earliest mechanisms elucidated for the activity of Fucoidans has been the binding with L- and P-selectin, members of a family of cell surface receptors involved in the inflammatory response.
- selectins mediate the binding and adhesion of cells expressing the selectins to other cells such as those on the endothelium upon cytokine activation (Bevilacqua MP, Nelson RM. Selectins. J Clin Invest. 1993 Feb;91(2):379-87).
- Fucoidan (Berteau O, Mulloy B. Sulfated fucans, fresh perspectives: structures, functions, and biological properties of sulfated fucans and an overview of enzymes active toward this class of polysaccharide. Glycobiology. 2003 Jun;13(6):29R-40R). Fucoidan has been shown to have immunomodulating effects by stimulating lymphocytes and macrophages (Choi EM, Kim AJ, Kim YO, Hwang JK. Immunomodulating activity of arabinogalactan and fucoidan in vitro. J Med Food. 2005 Winter;8(4):446-53).
- fucoidan can induce the mobilization of these stem cells to muscles (Sweeney EA, Priestley GV, Nakamoto B, Collins RG, Beaudet AL, Papayannopoulou T. Mobilization of stem/progenitor cells by sulfated polysaccharides does not require selectin presence. Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6544-9). This effect is most likely due to the observed effect of increasing SDF-I plasma levels (Sweeney EA, Lortat- Jacob H, Priestley GV, Nakamoto B, Papayannopoulou T.
- the supplemental composition comprises fucoidan.
- a serving of the supplemental composition comprises from about 0.01 g to about 0.1 g of fucoidan.
- the preferred dosage of a serving of the supplemental composition of the present invention comprises about 0.024 g of fucoidan.
- the supplemental composition comprises Laminaria japonica extract as a source of fucoidan.
- Sphinoglipids are important constituents of eukaryotic organisms.
- sphingolipids and their metabolic products are highly bioactive molecules which are involved in the regulation of many important biological functions including cell growth, differentiation and apoptosis (Vesper H, Schmelz EM, Nikolova- Karakashian MN, Dillehay DL, Lynch DV, Merrill AH Jr. Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr. 1999 Jul;129(7):1239- 50). Sphingolipid metabolism and biological function can be modulated by dietary intake of sphingolipids. Supplying supplemental sphingolipids promotes the synthesis of sphingosine 1 -phosphate.
- Sphingosine 1 -phosphate is a bioactive sphingolipid metabolite that has been shown to regulate a number of important biological functions including satellite cell activation (Nagata Y, Partridge TA, Matsuda R, Zammit PS. Entry of muscle satellite cells into the cell cycle requires sphingolipid signaling. J Cell Biol.
- the supplemental composition comprises a source of sphingolipids.
- a serving of the supplemental composition of the present invention comprises from about 0.005 g to about 0.05 g of a source of sphingolipids.
- the preferred dosage of a serving of the supplemental composition of the present invention comprises about 0.014 g of a source of sphingolipids.
- Resveratrol is a polyphenol found in many plant sources, most notably in grape skins, grape juice and red wine. One of the most abundant sources is from the roots of Polygonum cuspidatum. In plants, the biological function of resveratrol is as an antibiotic to fight infection. However, as a component of the diet, either as a constituent of plant-based foods or as a nutritional supplement, resveratrol has been reported to confer many health benefits. The main beneficial function of polyphenols from plant sources is generally attributed to antioxidant activity. However, resveratrol has been shown to increase NO production by tissue-specific induction of NOSs (Das S, Alagappan VK, Bagchi D, Sharma HS, Maulik N, Das DK.
- the supplemental composition of the present invention comprises Polygonum cuspidatum as a source of resveratrol.
- a serving of the supplemental composition of the present invention comprises from about 0.001 g to about 0.01 g of Polygonum cuspidatum as a source of resveratrol.
- the preferred dosage of a serving of the supplemental composition of the present invention comprises about 0.004 g of Polygonum cuspidatum as a source of resveratrol.
- the composition of the present invention comprises at least creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters of creatine and a source of fucoidan.
- the composition of the present invention comprises creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters of creatine, a source of fucoidan and a source of sphingolipids.
- the composition of the present invention comprises creatine or pharmaceutically acceptable derivatives of creatine such as salts and esters of creatine, a source of fucoidan, a source of sphinoglipids and a source of resveratrol.
- the compositions of the present invention may also comprise, in addition to the aforementioned constituents, any number of amino acids in sufficient quantities to be effective in inducing muscle hypertrophy, or salts or esters of said amino acids.
- proteins such as whey protein, casein protein, milk proteins, or soy protein, may further be included in the compositions of the present invention in quantities effective to induce muscle hypertrophy. Amino acids and proteins are well known in the art to aid in the generation and repair of muscle protein.
- composition of the present invention when used in conjunction with the method provided herein, induces muscle hypertrophy via satellite cells fusion to muscle fibres and induces the substantially simultaneous replenishment of myogenic precursor cell in response to exercise.
- a method for enhancing the effectiveness of the immune system in an individual comprises at least the step of administering to an individual a therapeutically effective and acceptable amount of the composition of the present invention.
- compositions of the present invention may be administered to a mammal via any therapeutically acceptable format.
- the compositions of the present invention may be administered to a mammal intravenously, intramuscularly, or interperitoneally as routes of administration distinct from the aforementioned oral method.
- routes of administration may also be combined with an oral administration of the composition of the present invention as an additional method of administration to a mammal.
- the nutritional supplement may be consumed in any form.
- the dosage form of the nutritional supplement may be provided as, e.g., a powder beverage mix, a liquid beverage, a ready-to-eat bar or drink product, a capsule, a liquid capsule, a tablet, a caplet, or as a dietary gel.
- the preferred dosage forms of the present invention are as a caplet or as a liquid capsule.
- the present composition may also be provided in various time-release formats, e.g. a slow-release format, a quick-release format, or a phase-release format, as are known in the art as well.
- the dosage form of the nutritional supplement may be provided in accordance with customary processing techniques for herbal and nutritional supplements in any of the forms mentioned above.
- the nutritional supplement set forth in the example embodiments herein may contain any appropriate number and type of excipients, as is well known in the art.
- the present nutritional composition or those similarly envisioned by one of skill in the art may be utilized in methods to support the biological function of muscle-specific progenitor cells required for skeletal muscle recovery and growth in response to exercise.
- the present compositions and method disclosed herein are provided to induce muscle hypertrophy via satellite cell fusion to muscle fibres and induce a substantially coincident replenishment of myogenic precursor cell in response to exercise.
- a nutritional supplement for inducing muscle hypertrophy via satellite cell fusion to muscle fibres and inducing a substantially simultaneous replenishment of myogenic precursor cell in response to exercise is provided.
- the nutritional supplement is in the form of caplets.
- One serving of the nutritional supplement is 7 caplets and each serving comprises:
- a nutritional supplement for inducing muscle hypertrophy via satellite cells fusion to muscle fibres and inducing a substantially simultaneous replenishment of myogenic precursor cell in response to exercise is provided.
- the nutritional supplement is in the form of caplets.
- One serving of the nutritional supplement is 7 caplets and each serving comprises:
- Laminaria japonica extract (standardized to 85% fucoidan), and about 0.0145 g of soy/milk sphingolipids.
- Example 3 A nutritional supplement for inducing muscle hypertrophy via satellite cells fusion to muscle fibres and inducing a substantially simultaneous replenishment of myogenic precursor cell in response to exercise is provided.
- the nutritional supplement is in the form of caplets.
- One serving of the nutritional supplement is 7 caplets and each serving comprises: [0052] about 3.5 g of creatine monohydrate (fine-milled), about 0.024 g of
- Laminaria japonica extract (standardized to 85% fucoidan), about 0.0145 g of soy/milk sphingolipids, and about 0.004 g of Polygonum cuspidatum,.
- a nutritional supplement for inducing muscle hypertrophy via satellite cells fusion to muscle fibres and inducing a substantially simultaneous replenishment of myogenic precursor cell in response to exercise is provided.
- the nutritional supplement is in the form of caplets.
- One serving of the nutritional supplement is 7 caplets and each serving comprises:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2007350793A AU2007350793A1 (en) | 2007-04-04 | 2007-04-04 | Composition for promoting the maintenance and function of muscle-specific progenitor cells |
EP07719475A EP2142195A4 (en) | 2007-04-04 | 2007-04-04 | Composition for promoting the maintenance and function of muscle-specific progenitor cells |
CA002682589A CA2682589A1 (en) | 2007-04-04 | 2007-04-04 | Composition for promoting the maintenance and function of muscle-specific progenitor cells |
PCT/CA2007/000545 WO2008122098A1 (en) | 2007-04-04 | 2007-04-04 | Composition for promoting the maintenance and function of muscle-specific progenitor cells |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2007/000545 WO2008122098A1 (en) | 2007-04-04 | 2007-04-04 | Composition for promoting the maintenance and function of muscle-specific progenitor cells |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008122098A1 true WO2008122098A1 (en) | 2008-10-16 |
Family
ID=39830423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2007/000545 WO2008122098A1 (en) | 2007-04-04 | 2007-04-04 | Composition for promoting the maintenance and function of muscle-specific progenitor cells |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2142195A4 (en) |
AU (1) | AU2007350793A1 (en) |
CA (1) | CA2682589A1 (en) |
WO (1) | WO2008122098A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010086746A3 (en) * | 2009-01-28 | 2010-09-30 | Life Science Nutrition As | Compositions and methods of treating viral infections |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110448A2 (en) * | 2004-05-07 | 2005-11-24 | Thermo Formulations Ltd. | Nutritional composition for increasing creatine uptake in skeletal muscle |
US20070020358A1 (en) * | 2005-03-18 | 2007-01-25 | Mower Thomas E | Sports drink concentrate |
-
2007
- 2007-04-04 EP EP07719475A patent/EP2142195A4/en not_active Withdrawn
- 2007-04-04 WO PCT/CA2007/000545 patent/WO2008122098A1/en active Application Filing
- 2007-04-04 AU AU2007350793A patent/AU2007350793A1/en not_active Abandoned
- 2007-04-04 CA CA002682589A patent/CA2682589A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110448A2 (en) * | 2004-05-07 | 2005-11-24 | Thermo Formulations Ltd. | Nutritional composition for increasing creatine uptake in skeletal muscle |
US20070020358A1 (en) * | 2005-03-18 | 2007-01-25 | Mower Thomas E | Sports drink concentrate |
Non-Patent Citations (8)
Title |
---|
DAS S. ET AL.: "Coordinated induction of iNOS-VEGF-KDR-eNOS after resvatrol consumption: a potential mechanism for resvatrol preconditioning of the heart", VASCULAR PHARMACOLOGY, vol. 42, no. 5-6, 2005, pages 281 - 289, XP004910836 * |
DONATI C. ET AL.: "Sphingosine 1-phosphate regulates myogenic differentiation: A major role for SIP2 receptor", THE FASEB JOURNAL, vol. 19, no. 3, 2005, pages 449 - 451, XP008119605 * |
DOYONNAS ET AL.: "Hematopoietic contribution to skeletal muscle regeneration by myelomonocytic precursors", PROC. NATL. ACAD. SCI., vol. 101, no. 37, 2004, pages 13507 - 13512, XP008119557 * |
LUYT ET AL.: "Low-molecular-weight fucoidan promotes therapeutic revasularization in a rat model of critical hindlimb ischemia", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 305, no. 1, 2003, pages 24 - 30, XP008039129 * |
NAGATA Y. ET AL.: "Entry of muscle satellite cells into the cell cycle requires sphingolipid signaling", THE JOURNAL OF CELL BIOLOGY, vol. 174, no. 2, 2006, pages 245 - 253, XP008119604 * |
See also references of EP2142195A4 * |
SWEENEY ET AL.: "Mobilization of stem/progenitor cells by sulfated polysaccharides does not require selectin presence", PROC. NATL. ACAD. SCI., vol. 97, no. 12, 2000, pages 6544 - 6549, XP008119556 * |
SWEENEY ET AL.: "Sulfated polysaccharides increase plasma levels of SDF-1 in monkeys and mice: involvement in mobilization of stem/progenitor cells", BLOOD, vol. 99, no. 1, 2002, pages 44 - 51, XP008119555 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010086746A3 (en) * | 2009-01-28 | 2010-09-30 | Life Science Nutrition As | Compositions and methods of treating viral infections |
US8697670B2 (en) | 2009-01-28 | 2014-04-15 | Life Science Nutrition As | Compositions and methods of treating viral infections |
US9789142B2 (en) | 2009-01-28 | 2017-10-17 | Life Science Nutrition As | Method of increasing lean body mass |
Also Published As
Publication number | Publication date |
---|---|
EP2142195A4 (en) | 2011-10-12 |
EP2142195A1 (en) | 2010-01-13 |
AU2007350793A1 (en) | 2008-10-16 |
CA2682589A1 (en) | 2008-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3130336A1 (en) | Food and/or nutraceutical composition containing pea | |
ES2458353T3 (en) | Preparation comprising amino acids and plants and their activity in alcohol detoxification and in the treatment of migraine | |
EP3393467B1 (en) | Compositions comprising nicotinamide riboside and a urolithin | |
US5840715A (en) | Dietary regimen of nutritional supplements for relief of symptoms of arthritis | |
US11123407B2 (en) | Nutritional composition for treating or preventing impaired mobility | |
TWI436774B (en) | Skin enhancers and their use | |
EP0951909B1 (en) | Combination composition comprising a L-carnitine or an alkanoyl-L-carnitine, a glycosaminoglycan and/or constituent thereof | |
KR20010079981A (en) | Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders | |
US20110160136A1 (en) | Polyphenols for the treatment of cartilage disorders | |
US20110028400A1 (en) | Sulfated unsaturated disaccharidic chondroitin sulfate in connective tissue protection and repair | |
EP2859896A1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
US20080249063A1 (en) | Composition for promoting the maintenance and function of muscle-specific progenitor cells | |
WO2008122098A1 (en) | Composition for promoting the maintenance and function of muscle-specific progenitor cells | |
US20060135444A1 (en) | Combination of flavonoid and procyanidin for the reduction of the mammalian appetite | |
KR101888955B1 (en) | Composition containing the alcohol extract of Lilium lancifolium for preventing, improving and treating of arthritis as effective component | |
JP6948774B2 (en) | Preadipocyte differentiation inhibitor containing urolithins | |
JP7168477B2 (en) | Food composition and osteoblast differentiation promoter | |
WO2024138056A2 (en) | Bioactive compositions and methods of use thereof | |
DOWNEY | FISH OIL | |
OSTEOMALACIA et al. | Nutrients Applied to Injury Rehabilitation and Sports Medicine 223 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07719475 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2682589 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007350793 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007719475 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007350793 Country of ref document: AU Date of ref document: 20070404 Kind code of ref document: A |